Skip to main content

The Impact of FDA Regulatory Activities on Incident Dispensing of LABA-Containing Medication: 2005-2011

Basic Details
Date
Type
Publication
Medical Product
long-acting beta2 agonist (LABA)
Health Outcome(s)
change in drug utilization patterns
Description

Evidence of safety issues associated with long-acting beta2-agonist (LABA) treatment has led to multiple regulatory activities by the U.S. Food and Drug Administration (FDA) on this class of medications.This study describes the impact of the regulatory activities on incident LABA-containing medication dispensing.

Materials

Journal of Asthma; 14 September 2017. DOI: 1080/02770903.2017.1378355

Related Assessment(s)
Long Acting Beta2 Agonists (LABA) Policies and Drug Utilization Patterns
Author(s)

Meghan A. Baker MD, ScD, Melissa G. Butler PharmD, PhD, MPH, Sally Seymour MD, Fang Zhang PhD, Yute Wu PhD, Ann Chen Wu MD, MPH, Mark S. Levenson PhD, Pingsheng Wu PhD, Aarthi Iyer MPH, Sengwee Toh ScD, Solomon Iyasu MD, MPH, Esther H. Zhou MD, PhD

Corresponding Author

E. H. Zhou, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA. Email: Esther.Zhou@fda.hhs.gov